Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Booker, P. D.
Right arrow Articles by Pozzi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Booker, P. D.
Right arrow Articles by Pozzi, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, 2000, Vol. 85, No. 2 205-210
© 2000 The Board of Management and Trustees of the British Journal of Anaesthesia

Enoximone pharmacokinetics in infants

P. D. Booker1,*, S. Gibbons1, J. I. M. Stewart2,3, A. Selby2, E. Wilson-Smith2 and M. Pozzi2

1University of Liverpool, Liverpool, 2Royal Liverpool Children’s NHS Trust, Alder Hey, Eaton Road, Liverpool L12 2AP, UK. 3Present address: Queen’s Medical Centre, Derby Road, Nottingham NG7 2UH, UK

Enoximone and enoximone sulphoxide concentrations were measured in plasma of 20 infants, median age 6.0 (range 0.6–49.7) weeks, during and after prolonged continuous infusions. Patients were given enoximone 1 mg kg–1 and an infusion at 10 µg kg–1 min–1 just before being weaned from cardiopulmonary bypass (CPB). The infusion was stopped when clinically indicated, after a median 97 (range 24–572) h. Arterial blood samples were taken 30 min and 12 h after CPB, every 24 h during the infusion, and then 2, 4, 8, 12 and 24 h after the infusion was stopped. Pharmacokinetic non-compartmental analysis was performed using TOPFIT software. Fourteen patients who retained normal hepatic function had a median (95% confidence intervals) clearance of 9.7 (6.3–14.1) ml min–1 kg–1, elimination half-life of 5.2 (2.4–6.8) h and a volume of distribution of 3.6 (2.0–5.7) litre kg–1. The six patients with significant hepatic dysfunction had a lower clearance, 5.7 (2.4–14.5) ml min–1 kg–1, and significantly longer elimination half-life, 7.6 (6.5–10.9) h (P=0.02). Enoximone sulphoxide elimination half-life was significantly prolonged in three patients with renal dysfunction, 16.2 (10.5–17.7) h versus 6.9 (6.1–9.4) h (P=0.03). These results confirm that enoximone pharmacokinetics in infants is similar to that found in adults. The infusion rate of enoximone should be reduced if hepatic or renal dysfunction supervenes.

Br J Anaesth 2000; 85: 205–10

* Corresponding author


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
Y. A. Zausig, D. F. Stowe, W. Zink, C. Grube, E. Martin, and B. M. Graf
A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts.
Anesth. Analg., June 1, 2006; 102(6): 1646 - 1652.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.